The ineffectiveness of chemotherapy in patients with pancreatic cancer highlights a critical
unmet need in pancreatic cancer therapy. Two commonly mutated genes in pancreatic …

Pancreatic adenocarcinoma (PDAC) remains a formidable disease that needs improved
therapeutic strategies. Even though immunotherapy has revolutionized treatment for various …

The investment in the ''War on Cancer''initiated by the National Cancer Act of 1971 is paying
off in terms of improved patient outcomes, with more than 65% of all cancer patients now …

Significant advances have been achieved in recent years in the identification of the genetic
and the molecular alterations of pancreatic ductal adenocarcinoma (PDAC). Despite this, at …

The discovery of biallelic, inactivating SMARCB 1 mutations in rhabdoid tumors (RTs) over a
decade ago represented the first recognized link between chromatin remodeling and tumor …

We used a cost-effective, non-invasive method to obtain high-quality DNA from buccal
epithelial-cells (BEC) of premature infants for genomic analysis. DNAs from BEC were …

Objective The progression of pleomorphic adenoma (PA) to carcinoma ex-pleomorphic
adenoma (CXPA) encompasses several genomic alterations involving complex pathways …

Introduction Hepatocellular carcinoma (HCC) has a high mortality rate worldwide. The
dysregulation of RNA splicing is a major event leading to the occurrence, progression, and …

BACKGROUND The majority of patients with pancreatic cancer who undergo curative
resection experience rapid disease recurrence. In previous small studies, high expression of …

Introduction: Despite recent progress, the outlook for most patients with pancreatic cancer
remains poor. There is variation in how patients are managed globally due to differing …